EMERALD-1: Durvalumab/Bevacizumab Plus TACE in Unresectable HCC

The FDA approved a phase 3 trial to assess amezalpat with the current standard of care in unresectable or metastatic hepatocellular carcinoma.

In this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers.

The FDA recently approved a phase 2 clinical trial to investigate the efficacy of leronlimab in patients with relapsed or refractory microsatellite-stable metastatic colorectal cancer.

In season 4, episode 16 of Targeted Talks, Susanne G. Warner, MD,discusses the importance of tailoring treatments for patients with liver cancer, taking into account the staging of the cancer.

The new drug application resubmission of rivoceranib/camrelizumab in the first line in unresectable or metastatic hepatocellular carcinoma is supported by the final survival analysis of CARES-310 trial.

This approval marks the first CLDN 18.2-targeted therapy in this patient population.